114results about How to "Increase transcriptional activity" patented technology

This invention describes the cloning and characterization of the promoter region for the PCA3^dd3 gene. This region regulates the PCA3^dd3 gene expression by a unique prostate specific transcriptional mechanism. The present invention relates to the use of this promoter region as a tool for prostate cancer treatment and diagnosis and screening of agents which regulate expression of PCA3. In a particular embodiment, the present invention relates to an isolated promoter sequence which comprises an isolated promoter sequence which comprises a sequence as set forth between nucleotide positions 372 to 460 of SEQ ID NO:1, this sequence enabling a prostate-specific modulation of transcription.

The invention relates to enhancer Hr3 adopting the nucleotide sequence shown in the SEQIDNO: 1. The enhancer Hr3 can be used for preparing and recombining heterologous protein by bombyx mori. The invention further relates to a recombination carrier containing the enhancer Hr3, and the recombination carrier is prepared in such a manner that the enhancer Hr3 is connected with a Nco1 restriction site at the upstream of a promoter of a carrier containing no enhancer through the Nco1 restriction site of the enhancer Hr3. In the invention, functional elements such as the first grade enhancer, activating transcription factor IE1, untranslated region sequences (5' UTR and 3' UTR) and the like which are expressed by intensifier are identified in the cellular level, and an efficient and stable sericin I expression system is built by integrating optimum elements on the basis, so that efficient expression recombination heterologous protein can be made of middle silk gland of transgenic bombyx mori.

The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified. N-terminal truncated forms of SMYD3 (alias ZNFN3A1) have higher methylating activity. Lys 824 is a preferred methylation site on the RB1 protein for SMYD3.

The invention discloses a DNA (Deoxyribose Nucleic Acid) with constitutive promoter activity, application of the DNA and a pichia pastoris expression vector. The DNA has a base sequence as shown in SEQ No.1 (Sequence Number); and the application of the DNA relates to the application of the DNA in construction of the pichia pastoris (Pinchia Pastoris) expression vector. The DNA disclosed by the invention has the constitutive promoter activity, and can activate the transcription of a downstream structural gene without an inductor; the transcriptional activity shows little change in four different culture mediums, namely, ethanol, methanol, glucose and glycerol; the promoter activity is efficient, and the efficiency of the initiation transcription is four times more than the pichia pastoris GAPDH (Reduced Glyceraldehyde-phosphate Dehydrogenase) promoter. The pichia pastoris expression vector, constructed by the DNA disclosed by the invention, can efficiently express the extrinsic protein without methanol induction, and the efficiency of expressing the extrinsic protein (Enhanced Green Fluorescent Protein) is about 6 to 8 times that of the expression system of the GAPDH promoter and 1.5 to 2 times that of the expression system of a TEF1 (Transcription Enhancer Factor 1) promoter.

The invention belongs to the technical field of gene engineering, particularly relates to a rubber tree RNA (ribonucleic acid) polymerase type III promoter, in particular to a rubber tree U6 gene promoter proHbU6.6 and further discloses a cloning method and an application of the rubber tree U6 gene promoter proHbU6.6. The rubber tree RNA polymerase type III promoter, namely the rubber tree endogenous U6 promoter proHbU6.6 is obtained by cloning in a Para rubber tree for the first time; the promoter is a rubber tree endogenous RNA polymerase type III promoter, has high transcriptional activity,and can drive expression of downstream sgRNA (small guide ribonucleic acid); the activity of the promoter and feasibility of the promoter applied to a rubber tree CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9) gene editing system are demonstrated by instantaneous conversion of rubber tree protoplast; and CRISPR/Cas9 mediated rubber tree genometarget editing is achieved.

The invention relates to a novel guide RNA (Ribonucleic Acid) expression cassette used in a CRISPR/Cas (Clustered Regularly Interspaced Short Palindromic Repeats) system. According to the guide RNA expression cassette, a 5S rRNA gene is adopted as a starter to start expression of guide RNA. The invention further provides a CRISPR/Cas system with the guide RNA expression cassette and a method for editing genomes by using the system. The guide RNA expression cassette, the CRISPR/Cas system and the genome edition method provided by the invention have the advantages of universality, high efficiency, convenience, accuracy and the like.

Methods and compositions are provided for the diagnosis and treatment of heart diseases relating to cardiac hypertrophy, and for the regulation of proliferation and differentiation of cardiomyocyte progenitors in vitro. The detection of expression of components of the BAF complex, including, without limitation, detection of expression of Brg1, provides useful methods for early detection, diagnosis, staging, and monitoring of conditions leading to hypertrophy and enlargement of the heart. Manipulation of Brg1 activity provides for therapeutic intervention in the development of cardiac hypertrophy, where methods of decreasing Brg1 activity, e.g. through inhibition of binding, decreasing expression, and the like, reduces cardiac hypertrophy.

The invention discloses a myrothecium roridum A553 trichothecene synthase gene Tri5 promoter and application thereof. The nucleotide sequence of a promoter is shown in SEQ ID NO.1. According to the promoter, through a chromosome walking technology, the upstream promoter sequence of the Tri5 gene is obtained, the core region of the promoter is predicted, and the myrothecium roridum A553 trichothecene synthase gene Tri5 promoter Tri5P is obtained. By means of the promoter, expression of a hygromycin resistance gene can be efficiently started, the starting efficiency is close to that of a constitutive promoter TEF1, and a molecular biology basis is laid for increasing the yield of trichothecene toxin and obtaining more novel trichothecene toxin with high activities through transcriptional regulation and heterologous expression in the later period.

The invention belongs to the technical field of gene engineering, and relates to a rubber tree RNA polymerase III type promoter, in particular to a rubber tree U6 gene promoter proHbU6.8. The invention further discloses a cloning method and application of the promoter. The rubber tree RNA polymerase III type promoter-rubber tree endogenous U6 promoter proHbU6.8 is obtained through cloning in a Brazil rubber tree for the first time. The promoter is the rubber tree endogenous RNA polymerase III-type promoter, the promoter has high-efficiency transcriptional activity, the expression of downstreamsgRNA can be driven, the activity of the promoter and the application feasibility of the promoter in a rubber tree CRISPR/Cas9 gene editing system are verified through transient transformation rubbertree protoplasm, and CRISPR/Cas9-mediated rubber tree genome targeted editing is achieved.

The invention discloses application of bavachinin and analogs of bavachinin. According to the application, bavachinin or/and analogs of bavachinin serve as active ingredients to prepare compositions for enhancing exciting activity of PPARalpha or/and PPARgamma. Research results show that bavachinin and analogs of bavachinin can remarkably improve the transcriptional activity of a PPARgamma exciting agent to PPARgamma, enhance the transcriptional activity of a PPARalpha exciting agent to PPARalpha and serve as active ingredients of PPARalpha or/and PPARgamma exciting agents to prepare compositions for preventing or treating the metabolic syndrome, the application range of bavachinin and analogs of bavachinin can be widened, and decrement and synergism of PARalpha or/and PPARgamma exciting agents can be achieved to reduce the toxic and side effects of PARalpha or/and PPARgamma exciting agents and achieve wide clinical application of PARalpha or/and PPARgamma exciting agents.

The invention discloses a DNA fragment with a promoter function and a use thereof. The DNA fragment has a sequence selected from (a), a nucleotide sequence shown in the formula of SEQ ID NO. 1 or its complementary sequence, (b), a nucleotide sequence which is derived from the nucleotide sequence shown in the formula of SEQ ID NO. 1 through replacement, deletion or addition of one or multiple nucleotides and has a promoter function the same to that of the nucleotide sequence shown in the formula of SEQ ID NO. 1, or its complementary sequence, and (c), a sequence derived from the nucleotide sequence shown in the formula of SEQ ID NO. 1 through addition of one or more ribosome binding sites. The DNA fragment has a promoter function and strong specific expression activity, realizes high exogenous gene expression without an inducer and provides an effective element for bacillus subtilis expression of an exogenous gene.

The invention provides a novel method for generating stable mammalian cell lines with enhanced protein production capabilities, and to expression vectors and related methods for high level expression of biopharmaceutical proteins of interest.

The invention relates to a chimeric promoter construct useful for neuronal cell specific gene expression. The invention provides a recombinant nucleic acid molecule that comprises a neuronal cell specific promoter such as platelet-derived growth factor β-chain promoter, operably linked to a heterologous enhancer which enhances the transcriptional activity of the promoter, such as cytomegalovirus immediate early gene enhancer. The promoter construct according to the invention can increase and prolong gene expression in neuronal cells and may be advantageously used in gene therapy of neuronal disorders.

The invention discloses a promoter of a trichothecene synthase gene Tri12 of Leucosphaeria dothidea A553 and the application of the promoter. The nucleotide sequence of the promoter is as shown in SEQID NO. 1. According to the invention, an upstream promoter sequence of the Tri12 gene is obtained through a chromosome walking technology, and a promoter core region is predicted so as to obtain thepromoter Tri12P of the trichothecene synthase gene Tri12 of the Leuconostoc dunalianum A553. The promoter can efficiently start expression of the hygromycin resistance gene hph, and the starting efficiency is similar to the starting efficiency of a constitutive promoter TEF1, so a molecular biological foundation is laid for increasing the yield of trichothecene toxin and obtaining more high-activity novel trichothecene toxin through transcription regulation and heterologous expression in a later period.

The present invention identified OVARC1000473 (SEQ ID NO: 1) and NT2RM1000377 (SEQ ID NO: 3) as clones showing suppression of CREB activation by forskolin, and provides evaluation methods using these genes, and/or proteins encoded by these genes. Furthermore, these proteins were found to enhance cell damage. Compounds that can be screened based on the evaluation methods of this invention are useful as agents for inhibiting the CREB dephosphorylation reaction, agents for suppressing enhancement of cell damage, and preventive and therapeutic agents for memory disorders and/or neurodegenerative disorders.

The invention discloses a pulmonary hypertension virulence gene ACVRL1 mutation site and an application thereof. The amino acid sequence of a protein provided by the invention is sequence 4. The DNA molecule of the protein is coded and the nucleotide sequence of the DNA molecule is sequence 2. The experiment shows that the novel ACVRL1 gene mutation site is related to the pulmonary hypertension, by means of detecting whether the novel gene mutation site is the mutation site, whether the sample to be tested suffers from pulmonary hypertension can be predicted; and the novel gene mutation site can be used as a target for treating the pulmonary hypertension, and a new therapy pathway for researching the pulmonary hypertension drugs can be provided. The cell experiment verifies that the ACVRL1 gene mutation site is capable of reducing the SMAD1 and SMAD5 protein phosphorylation and/or increasing the BMP transcriptional activity in the cell.

The invention belongs to the technical field of severe asthma action mechanisms, and discloses a medicine for relieving severe asthma, application and an animal model construction method, the medicine is an HDAC10 inhibitor, and the action mechanism of HDAC10 for regulating and controlling Th17/IL-17A expression in severe asthma is clarified by using the construction method; the interaction mode of HDAC10 and STAT3 is defined; it is proved that HDAC10 deacetylated STAT3 regulates and controls the expression of Th17/IL-17A in severe asthma. it is determined that the HDAC10 inhibitor can relieve severe asthma, and an experimental basis is provided for HDAC10 targeted therapy of severe asthma. it is determined that the HDAC10 inhibitor can relieve severe asthma, and an experimental basis is provided for HDAC10 targeted therapy of severe asthma. Compared with a control group, the intraperitoneal injection of the HDAC10 inhibitor can improve airway inflammation, airway hyperreactivity and airway mucus secretion of a severe asthma mouse model mainly comprising neutrophile granulocytes.

The invention discloses a promoter. The length of the promoter is 150-1000bp, wherein the promoter comprises a nucleic acid fragment expressed as SEQ ID NO.1; the promoter is capable of starting the transcription in bacillus subtilis. The invention also provides a recombinant expression vector; a reading frame is allowed to be inserted into the recombinant expression vector and is used for expressing protein in bacteria; a promoter of the recombinant expression vector comprises the promoter. The invention further provides a method for expressing heterologous proteins. The method comprises a step of inserting the reading frame for encoding the heterologous proteins into the recombinant expression vector to prepare recombinant expression plasmids. The invention also provides application of the promoter to preparation of the recombinant expression vector and/or expressing the proteins in the plasmids. By virtue of the technical scheme, the expression quantity of the heterologous proteins can be obviously increased without induction.